Pharmacokinetics of vinpocetine in humans.

L. Vereczkey, G. Czira, J. Tamás, Z. Szentirmay, Z. Botár, L. Szporny

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

The pharmacokinetics of ethyl-apovincaminate (vinpocetine, Cavinton), a new vincamine derivative has been studied in volunteers after p.o. and i.v. administration. The concentration of the drug was determined by mass-fragmentography in human plasma. There was a biphasic elimination of the substance after i.v. injection with a T1/2 alpha of 0.136 h and with a T1/2 beta of 4.83 h. The value of Vdss (2.1 l/kg) shows a high adsorption of the drug by tissue proteins. The clearance rate of elimination was 0.366 l/h/kg. Oral administration of the drug resulted in maximum plasma concentration 1--1.5 h after the administration with values of 20--62 ng/ml. The bioavailability of the drug--calculated from the ratio of the areas under the concentration-time curves--proved to be 56.6 +/- 8.9%. Unchanged vinpocetine could not be detected in urine. From the results two-compartment open models were constructed and the steady state concentrations after multiple dosing were computed.

Original languageEnglish
Pages (from-to)957-960
Number of pages4
JournalArzneimittel-Forschung
Volume29
Issue number6
Publication statusPublished - 1979

Fingerprint

vinpocetine
Pharmacokinetics
Pharmaceutical Preparations
Vincamine
Plasma (human)
Biological Availability
Adsorption
Oral Administration
Volunteers
Urine
Tissue
Derivatives
Plasmas
Injections

ASJC Scopus subject areas

  • Chemistry(all)
  • Organic Chemistry
  • Drug Discovery
  • Pharmacology

Cite this

Vereczkey, L., Czira, G., Tamás, J., Szentirmay, Z., Botár, Z., & Szporny, L. (1979). Pharmacokinetics of vinpocetine in humans. Arzneimittel-Forschung, 29(6), 957-960.

Pharmacokinetics of vinpocetine in humans. / Vereczkey, L.; Czira, G.; Tamás, J.; Szentirmay, Z.; Botár, Z.; Szporny, L.

In: Arzneimittel-Forschung, Vol. 29, No. 6, 1979, p. 957-960.

Research output: Contribution to journalArticle

Vereczkey, L, Czira, G, Tamás, J, Szentirmay, Z, Botár, Z & Szporny, L 1979, 'Pharmacokinetics of vinpocetine in humans.', Arzneimittel-Forschung, vol. 29, no. 6, pp. 957-960.
Vereczkey L, Czira G, Tamás J, Szentirmay Z, Botár Z, Szporny L. Pharmacokinetics of vinpocetine in humans. Arzneimittel-Forschung. 1979;29(6):957-960.
Vereczkey, L. ; Czira, G. ; Tamás, J. ; Szentirmay, Z. ; Botár, Z. ; Szporny, L. / Pharmacokinetics of vinpocetine in humans. In: Arzneimittel-Forschung. 1979 ; Vol. 29, No. 6. pp. 957-960.
@article{0cfd65b4be2b433a9fd4710b40139f63,
title = "Pharmacokinetics of vinpocetine in humans.",
abstract = "The pharmacokinetics of ethyl-apovincaminate (vinpocetine, Cavinton), a new vincamine derivative has been studied in volunteers after p.o. and i.v. administration. The concentration of the drug was determined by mass-fragmentography in human plasma. There was a biphasic elimination of the substance after i.v. injection with a T1/2 alpha of 0.136 h and with a T1/2 beta of 4.83 h. The value of Vdss (2.1 l/kg) shows a high adsorption of the drug by tissue proteins. The clearance rate of elimination was 0.366 l/h/kg. Oral administration of the drug resulted in maximum plasma concentration 1--1.5 h after the administration with values of 20--62 ng/ml. The bioavailability of the drug--calculated from the ratio of the areas under the concentration-time curves--proved to be 56.6 +/- 8.9{\%}. Unchanged vinpocetine could not be detected in urine. From the results two-compartment open models were constructed and the steady state concentrations after multiple dosing were computed.",
author = "L. Vereczkey and G. Czira and J. Tam{\'a}s and Z. Szentirmay and Z. Bot{\'a}r and L. Szporny",
year = "1979",
language = "English",
volume = "29",
pages = "957--960",
journal = "Drug Research",
issn = "2194-9379",
publisher = "Thieme",
number = "6",

}

TY - JOUR

T1 - Pharmacokinetics of vinpocetine in humans.

AU - Vereczkey, L.

AU - Czira, G.

AU - Tamás, J.

AU - Szentirmay, Z.

AU - Botár, Z.

AU - Szporny, L.

PY - 1979

Y1 - 1979

N2 - The pharmacokinetics of ethyl-apovincaminate (vinpocetine, Cavinton), a new vincamine derivative has been studied in volunteers after p.o. and i.v. administration. The concentration of the drug was determined by mass-fragmentography in human plasma. There was a biphasic elimination of the substance after i.v. injection with a T1/2 alpha of 0.136 h and with a T1/2 beta of 4.83 h. The value of Vdss (2.1 l/kg) shows a high adsorption of the drug by tissue proteins. The clearance rate of elimination was 0.366 l/h/kg. Oral administration of the drug resulted in maximum plasma concentration 1--1.5 h after the administration with values of 20--62 ng/ml. The bioavailability of the drug--calculated from the ratio of the areas under the concentration-time curves--proved to be 56.6 +/- 8.9%. Unchanged vinpocetine could not be detected in urine. From the results two-compartment open models were constructed and the steady state concentrations after multiple dosing were computed.

AB - The pharmacokinetics of ethyl-apovincaminate (vinpocetine, Cavinton), a new vincamine derivative has been studied in volunteers after p.o. and i.v. administration. The concentration of the drug was determined by mass-fragmentography in human plasma. There was a biphasic elimination of the substance after i.v. injection with a T1/2 alpha of 0.136 h and with a T1/2 beta of 4.83 h. The value of Vdss (2.1 l/kg) shows a high adsorption of the drug by tissue proteins. The clearance rate of elimination was 0.366 l/h/kg. Oral administration of the drug resulted in maximum plasma concentration 1--1.5 h after the administration with values of 20--62 ng/ml. The bioavailability of the drug--calculated from the ratio of the areas under the concentration-time curves--proved to be 56.6 +/- 8.9%. Unchanged vinpocetine could not be detected in urine. From the results two-compartment open models were constructed and the steady state concentrations after multiple dosing were computed.

UR - http://www.scopus.com/inward/record.url?scp=0018336799&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018336799&partnerID=8YFLogxK

M3 - Article

VL - 29

SP - 957

EP - 960

JO - Drug Research

JF - Drug Research

SN - 2194-9379

IS - 6

ER -